Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | ACP3 | P15309 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 3/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL460126 | 0.91 | CA2 (0.44) | CA2SSTR4HTR1ASIGMAR1ADRA2A | |
| SCHEMBL30070640 | 0.91 | CA2 (0.44) | CA2SSTR4HTR1ASIGMAR1ADRA2A | |
| SCHEMBL8981650 | 0.84 | CA2 (0.40) | CA2SSTR4HTR1ASIGMAR1ADRA2A | |
| Flavane SCHEMBL10624050 | 0.82 | ESR1 (0.48) | — | |
| Flavane SCHEMBL27764824 | 0.81 | ESR1 (0.47) | — | |
| Propionic Acid SCHEMBL28970782 | 0.81 | CA2 (0.42) | CA2SSTR4HTR1ASIGMAR1ADRA2A | |
| SCHEMBL16964715 | 0.80 | TSHR (0.39) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL29767007 | 0.79 | CA2 (0.41) | CA2SSTR4HTR1ASIGMAR1ADRA2A | |
| Salicylic Acid SCHEMBL7597669 | 0.77 | ALDH1A1 (0.50) | CA2SSTR4HTR1ASIGMAR1ADRA2A | |
| Valine SCHEMBL11879625 | 0.74 | SLC7A5 (0.39) | CA2SSTR4HTR1ASIGMAR1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9168216-B2 | Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof | VITAL HEALTH SCIENCES PTY. LTD. (AU) | 2015-10-27 | — | — | US | claimed |
| US-20090036354-A1 | CARRIER COMPRISING ONE OR MORE DI AND/OR MONO-(ELECTRON TRANSFER AGENT) PHOSPHATE DERIVATIVES OR COMPLEXES THEREOF | ISP INVESTMENTS LLC | 2009-02-05 | — | — | US | claimed |
| EP-1893159-A1 | A CARRIER COMPRISING ONE OR MORE DI AND/OR MONO-(ELECTRON TRANSFER AGENT) PHOSPHATE DERIVATIVES OR COMPLEXES THEREOF | Vital Health Sciences Pty Ltd. (AU) | 2008-03-05 | — | — | EP | claimed |
| WO-2006133506-A1 | A CARRIER COMPRISING ONE OR MORE DI AND/OR MONO-(ELECTRON TRANSFER AGENT) PHOSPHATE DERIVATIVES OR COMPLEXES THEREOF | VITAL HEALTH SCIENCES PTY LTD (AU) | 2006-12-21 | — | — | WO | claimed |
| EP-2548581-A2 | A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof | Vital Health Sciences Pty Ltd. (AU) | 2013-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036354-A1 | CARRIER COMPRISING ONE OR MORE DI AND/OR MONO-(ELECTRON TRANSFER AGENT) PHOSPHATE DERIVATIVES OR COMPLEXES THEREOF | ADH1A, PC, PHOSPHO1 | OPRK1 4144/4885CA2 1775/4885ACP3 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.